Macrolide antibiotics for bronchiectasis

Altenburg J Wilms E Boersma W The relationship between serum- and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment Pneumologie 2016 A3 10.1055/s-0036-1592227

Altenburg J Wolf R Go S van Rijn P Boersma W van der Werf T Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment European Respiratory Journal 2016 OA278 10.1183/13993003.congress-2016.OA278

Altenburg J de Graaf C van der Werf T Boersma W Long term azithromycin treatment: A randomised placebo-controlled trial in non-CF bronchiectasis; results from the BAT trial European Respiratory Journal 2011 1924

Altenburg, 2013, Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial, JAMA, 309, 1251, 10.1001/jama.2013.1937

Boersma WG Altenburg J Werf TS Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis American Journal of Respiratory and Critical Care Medicine 2012 A3658

Asintam P Kiranantawat N Juthong S Can roxithromycin improve quality of life in bronchiectatic patients? European Respiratory Journal 2012 P2168

Cymbala, 2005, The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis, Treatments in Respiratory Medicine, 4, 117, 10.2165/00151829-200504020-00005

Diego, 2013, Effects of long-term azithromycin therapy on airway oxidative stress markers in non-cystic fibrosis bronchiectasis, Respirology, 18, 1056, 10.1111/resp.12130

Juthong S Eiamsaard S The effects of roxithromycin as anti-inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study European Respiratory Journal 2011 455s

Koh, 1997, Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study, European Respiratory Journal, 10, 994, 10.1183/09031936.97.10050994

Liu, 2012, [Impact of treatment with low dose roxithromycin on stable bronchiectasis], Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua jiehe he huxi zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases, 35, 824

Liu, 2014, Effect of low-dose, long-term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis, Mediators of Inflammation, 2014, 708608, 10.1155/2014/708608

Lourdesamy Anthony, 2014, Efficacy of azithromycin in the treatment of bronchiectasis, Respirology (Carlton, Vic.), 19, 1178, 10.1111/resp.12375

Masekela R Anderson R Gongxeka H Steel HC Green RJ Lack of efficacy of erythromycin in children with human immunodeficiency virus-related bronchiectasis - a randomised controlled trial Paediatric Respiratory Reviews 2013 S82/A009 12 http://dx.doi.org/10.1016/S1526-0542(13)70150-7

Masekela, 2013, Lack of efficacy of an immunomodulatory macrolide in childhood HIV-related bronchiectasis: a randomised, placebo-controlled trial, Journal of Antivirals and Antiretrovirals, 5, 44

Sadigov AS Mammadov GT Azythromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis: how we can improve the clinical features of severe disease? American Journal of Respiratory and Critical Care Medicine 2013 A3512

Burr L Rogers G Taylor S McGuckin M Serisier D Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non-CF bronchiectasis subjects Respirology 2015 29

Burr, 2016, Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non-cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low-dose erythromycin study trial, Annals of the American Thoracic Society, 13, 1697

Chen AC Martin MM Burr L Hasnain SZ Lourie R Bowler SD Clinical benefits of long-term, low-dose erythromycin in bronchiectasis are not due to anti-inflammatory effects American Journal of Respiratory and Critical Care Medicine 2013 A5970

Rogers GB Bruce KD Martin ML Burr LD Serisier DJ Corrections. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial Lancet Respiratory Medicine 2015 e15

Rogers, 2014, The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial, Lancet Respiratory Medicine, 2, 988, 10.1016/S2213-2600(14)70213-9

Serisier DJ Bowler SD McGuckin M Chen A Lourie A Martin ML Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial American Journal of Respiratory and Critical Care Medicine 2012 A6862

Serisier, 2013, Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial, JAMA, 309, 1260, 10.1001/jama.2013.2290

Hare, 2015, Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long-term azithromycin or placebo, European Journal of Clinical Microbiology and Infectious Diseases, 34, 2275, 10.1007/s10096-015-2480-0

Singleton R Morris P Leach A Roseby R White A Valery P Respirology 2008 A19

Singleton R Morris P Leach A Roseby R White A Valery PC BIS - Multi-centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children Respirology 2007 A 192

Valery, 2013, Long-term azithromycin for indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial, Lancet Respiratory Medicine, 1, 610, 10.1016/S2213-2600(13)70185-1

Wong, 2012, Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial, Lancet, 380, 660, 10.1016/S0140-6736(12)60953-2

Wong CA Jayaram L Karalus N Eaton T Tong C Hockey H Azithromycin decreases exacerbations in non-cystic fibrosis bronchiectasis American Journal of Respiratory and Critical Care Medicine 2012a A3657

Yalcin, 2006, Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis, Journal of Clinical Pharmacy and Therapeutics, 31, 49, 10.1111/j.1365-2710.2006.00708.x

Chang, 2013, Bronchiectasis exacerbation study on azithromycin and amoxicillin-clavulanate for respiratory exacerbations in children (BEST-2): study protocol for a randomized controlled trial, Trials, 14, 14

Kudo, 1988, Preclinical and clinical studies on TE-031 (A-56268) in treatment of bacterial respiratory tract infections, Chemotherapy, 36, 617

Min, 1988, Clinical evaluation of TE-031 in the chronic respiratory infections [Japanese], Japanese Pharmacology and Therapeutics, 16, 3027

Ming, 2005, Efficacy of macrolide and theophylline in the management of bronchiectasis, Respirology, 10, A168

Rikitomi, 1988, Preclinical and clinical studies on TE-031 (A-56268) in treatment of bacterial respiratory tract infections, Chemotherapy, 36, 715

Saito, 1988, Clinical studies of TE-031 (A-56268), Chemotherapy, 38, 576

Tagaya, 2002, Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion, Chest, 122, 213, 10.1378/chest.122.1.213

Unoura, 1988, Clinical study on TE-031(A-56268) against respiratory infections, Physicians' Therapy Manual, 36, 544

Tsang, 1999, A pilot study of low-dose erythromycin in bronchiectasis, European Respiratory Journal, 13, 361, 10.1183/09031936.99.13236199

Tsang KW Ho PL Chan KN Ip M Lam WK Lam B Erythromycin (EM) reduces sputum volume and improves lung functions in bronchiectasis American Thoracic Society International Conference; 1998 April 24-29; Chicago 1998 A174

Albert, Azithromycin for prevention of exacerbations of COPD, New England Journal of Medicine, 365, 689, 10.1056/NEJMoa1104623

Aliberti, 2016, Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration, European Respiratory Journal, 48, 632, 10.1183/13993003.01888-2015

Amsden, 2005, Anti-inflammatory effects of macrolides - an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?, Journal of Antimicrobial Chemotherapy, 55, 10, 10.1093/jac/dkh519

Brodt, 2014, Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review, European Respiratory Journal, 44, 382, 10.1183/09031936.00018414

Chalmers, 2012, Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis, American Journal of Respiratory and Critical Care Medicine, 186, 657, 10.1164/rccm.201203-0487OC

Chalmers, 2014, The Bronchiectasis Severity Index: an international derivation and validation study, American Journal of Respiratory and Critical Care Medicine, 189, 576, 10.1164/rccm.201309-1575OC

Chang, 2002, Bronchiectasis in indigenous children in remote Australian communities, Medical Journal of Australia, 177, 200, 10.5694/j.1326-5377.2002.tb04733.x

Chang, 2010, Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand: a position statement from the Thoracic Society of Australia and New Zealand and the Australian Lung Foundation, Medical Journal of Australia, 193, 356, 10.5694/j.1326-5377.2010.tb03949.x

Gibson GJ Loddenkemper R Sibille Y Lundbäck B editor(s) European Lung White Book: Respiratory Health and Disease in Europe. European Respiratory Society, 2013 https://www.erswhitebook.org/

Finch, 2015, A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis, Annals of the American Thoracic Society, 12, 1602

Gao, Macrolide therapy in adults and children with non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis, PLoS One, 3, e90047

Goeminne, 2016, Bronchiectasis: how to be an orphan with many parents?, European Respiratory Journal, 47, 10, 10.1183/13993003.01567-2015

McMaster University (developed by Evidence Prime) GRADEproGDT 2015

Habesoglu, 2011, Clinical, radiologic, and functional evaluation of 304 patients with bronchiectasis, Annals of Thoracic Medicine, 6, 131, 10.4103/1817-1737.82443

Hansen, 2015, Adverse events in patients taking macrolide antibiotics versus placebo for any indication, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD011825

Haworth, 2014, Long term macrolide maintenance therapy in non-CF bronchiectasis: evidence and questions, Respiratory Medicine, 108, 1397, 10.1016/j.rmed.2014.09.005

Higgins JP Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org

Hnin, 2015, Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD001392.pub3

Joish, 2013, Economic burden of non-cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective, Applied Health Economics and Health Policy, 11, 299, 10.1007/s40258-013-0027-z

Kapur, 2012, The burden of disease in pediatric non-cystic fibrosis bronchiectasis, Chest, 141, 1018, 10.1378/chest.11-0679

Kohler, 2010, Quorum sensing inhibition selects for virulence and co-operation in Pseudomonas aeruginosa, PLoS Pathogens, 6, e1000883, 10.1371/journal.ppat.1000883

Kwak, 2010, High prevalence of bronchiectasis in adults: analysis of CT findings in a health screening program, Tohoku Journal of Experimental Medicine, 222, 237, 10.1620/tjem.222.237

Leclercq, 2002, Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications, Clinical Infectious Diseases, 34, 482, 10.1086/324626

Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org

Martínez-García, 2007, Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis, Chest, 132, 1565, 10.1378/chest.07-0490

Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, PLoS Medicine, 6, e1000097, 10.1371/journal.pmed.1000097

Pasteur, 2010, British Thoracic Society Guidelines for Non-CF Bronchiectasis, Thorax, 65(Suppl 1), i1, 10.1136/thx.2010.136119

Quint, 2016, Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study, European Respiratory Journal, 47, 186, 10.1183/13993003.01033-2015

Ray, 2012, Azithromycin and the risk of cardiovascular death, New England Journal of Medicine, 366, 1881, 10.1056/NEJMoa1003833

The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014

Ringshausen, 2015, Bronchiectasis in Germany: a population-based estimation of disease prevalence, European Respiratory Journal, 46, 1805, 10.1183/13993003.00954-2015

Roberts, 2010, Trends in bronchiectasis mortality in England and Wales, Respiratory Medicine, 104, 981, 10.1016/j.rmed.2010.02.022

Saiman, 2003, Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial, JAMA, 290, 1749, 10.1001/jama.290.13.1749

Seitz, 2010, Trends and burden of bronchiectasis-associated hospitalizations in the United States, Chest, 138, 944, 10.1378/chest.10-0099

Seitz, 2012, Trends in bronchiectasis among Medicare beneficiaries in the United States, 2000-2007, Chest, 142, 432, 10.1378/chest.11-2209

Serisier, 2013, Risk of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases, Lancet Respiratory Medicine, 1, 262, 10.1016/S2213-2600(13)70038-9

Twiss, 2005, New Zealand national incidence of bronchiectasis "too high" for a developed country, Archives of Disease in Childhood, 90, 737, 10.1136/adc.2004.066472

Welsh, 2015, Interventions for bronchiectasis: an overview of Cochrane systematic reviews, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD010337.pub2

Weycker, 2005, Prevalence and economic burden of bronchiectasis, Clinical Pulmonary Medicine, 12, 205, 10.1097/01.cpm.0000171422.98696.ed

Wurzel, 2011, Short courses of antibiotics for children and adults with bronchiectasis, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD008695.pub2

Zarogoulidis, 2012, Macrolides from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases, European Journal of Clinical Pharmacology, 68, 479, 10.1007/s00228-011-1161-x

Kelly, 2016, Macrolide antibiotics for non-cystic fibrosis bronchiectasis, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD012406